Answers are grounded in this paper and cite their sources.
Marine-Lenhart syndrome (MLS), characterized by Graves' disease coexisting with autonomously functioning thyroid nodule (s), presents distinctive diagnostic and therapeutic challenges. Recent emphasis on thyroid scintigraphy has highlighted the potential "unmasking" of initially suppressed nodules. However, this phenomenon should not be interpreted as evidence that every initially cold nodule represents a latent autonomously functioning nodule, because scintigraphic appearance reflects functional status at a particular point in time and predictors of subsequent autonomous function remain incompletely defined. Moreover, functional autonomy and malignancy risk represent distinct diagnostic dimensions. Scintigraphy characterizes thyroid function but cannot establish histological benignity. Conversely, although hyperfunctioning nodules have a very low but non-zero risk of malignancy and routine cytological evaluation is generally not recommended, scintigraphic hyperfunction alone does not establish histological benignity. Ultrasonographic risk assessment remains complementary to functional imaging, and fine-needle aspiration should be considered when clinically appropriate, particularly in the presence of highly suspicious or discordant ultrasonographic findings or suspicious cervical lymph nodes. Similarly, observations that some patients require higher radioiodine activities or repeat treatment should not be equated with an established universal dosing strategy, given the predominantly case-based evidence underlying the MLS literature. Nuclear medicine imaging remains indispensable for functional characterization in MLS, but its interpretation should recognize "unmasking" as a changing functional phenotype rather than a definitive diagnostic endpoint.
No takes yet. Share an insight, caveat, or question.
Shinichiro M. Koga (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: